Immunology Today—May 27, 2026

This week’s Immunology update highlights regulatory progress, reimbursement momentum, clinical expansion, and emerging immune-modulating therapies.

In Today’s Newsletter

Dive deeper

💊 Korea weighs Crohn’s nutrition support expansion [1] [South Korea • 22 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31770
Context: Korea’s Ministry of Health and Welfare discussed enteral nutrition support with the Korean Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
Key point: Authorities are considering targeted additional support for pediatric and adolescent Crohn’s disease patients with high unmet need.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Gazyva gains Canadian reimbursement recommendation [2] [Canada • 24 May 2026]

https://www.biospace.com/press-releases/gazyva-obinutuzumab-receives-positive-reimbursement-recommendation-from-canadas-drug-agency-cda-amc-for-adults-with-active-lupus-nephritis
Context: CDA-AMC recommended Gazyva (obinutuzumab, Roche Canada) for adults with active lupus nephritis receiving standard therapy.
Key point: Roche said the recommendation follows Health Canada authorization and is supported by Phase 3 REGENCY data.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Qihan’s QT-019C IND cleared by FDA [3] [US • 20 May 2026]

https://www.businesswire.com/news/home/20260519867791/en/Qihan-Biotech-Announces-FDA-Clearance-of-IND-for-QT-019C-a-universal-dual-target-CAR-T-candidate-marking-a-significant-milestone-in-the-development-of-a-potentially-low-lymphodepletion-off-the-shelf-CAR-T-therapy-for-autoimmune-diseases
Context: QT-019C is Qihan Biotech’s universal allogeneic dual-target CAR-T candidate for autoimmune diseases.
Key point: FDA cleared the IND, enabling human clinical trials of a potentially low-lymphodepletion, off-the-shelf CAR-T approach.
Implication: Signals pipeline investment and modality expansion.

🧴 Galderma wins Differin Epiduo OTC switch [4] [US • 22 May 2026]

https://www.businesswire.com/news/home/20260522074280/en/Galderma-Receives-U.S.-FDA-Approval-for-Differin-Epiduo-Acne-Gel-Prescription-to-OTC-Switch
Context: Differin Epiduo Acne Gel combines adapalene 0.1% and benzoyl peroxide 2.5% for acne treatment.
Key point: FDA approved the prescription-to-OTC switch for people aged 12 years and older, with US retail availability planned for summer 2026.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🔬 FibroBiologics reports CYPS317 psoriasis data [5] [US • 22 May 2026]

https://www.globenewswire.com/news-release/2026/05/22/3300109/0/en/fibrobiologics-presents-preclinical-data-demonstrating-durable-immunomodulation-in-psoriasis-at-the-society-for-investigative-dermatology-2026-annual-meeting.html
Context: FibroBiologics presented CYPS317 preclinical psoriasis data at the Society for Investigative Dermatology 2026 Annual Meeting.
Key point: Human dermal fibroblast spheroids reduced disease severity, prevented relapse, and suppressed inflammatory pathways in animal models.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Access: Korea’s Crohn’s nutrition proposal and Galderma’s OTC switch both point to broader patient access models.
Immunology: Gazyva’s CDA-AMC recommendation adds payer momentum in lupus nephritis.
Cell therapy: Qihan and FibroBiologics highlight continued investment in next-generation immune-modulating modalities.
Evidence maturity varies: Gazyva cites Phase 3 data, while CYPS317 remains preclinical.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Immunology archive on our research hub page.

FAQ

What is Korea considering for pediatric Crohn’s disease?

The Ministry of Health and Welfare is considering targeted additional enteral nutrition support for children and adolescents with Crohn’s disease, focused on patients with the greatest unmet need. [1]

What did CDA-AMC recommend for Gazyva?

CDA-AMC recommended Gazyva (obinutuzumab, Roche Canada) for public reimbursement in adults with active lupus nephritis receiving standard therapy. [2]

What is QT-019C?

QT-019C is Qihan Biotech’s universal allogeneic dual-target CAR-T candidate for autoimmune diseases, designed to explore a low-lymphodepletion approach. [3]

What changed for Differin Epiduo Acne Gel?

FDA approved Differin Epiduo Acne Gel for over-the-counter use in people aged 12 years and older in the US. [4]

What did FibroBiologics report for CYPS317?

FibroBiologics reported preclinical psoriasis data showing durable immunomodulation with human dermal fibroblast spheroids in animal models. [5]

Entities / Keywords

Korea Ministry of Health and Welfare, Korean Society of Pediatric Gastroenterology, Hepatology, and Nutrition, Crohn’s disease, enteral nutrition
Roche Canada, Gazyva, obinutuzumab, CDA-AMC, Health Canada, lupus nephritis, REGENCY
Qihan Biotech, QT-019C, universal allogeneic CAR-T, autoimmune diseases, lymphodepletion
Galderma, Differin Epiduo, adapalene, benzoyl peroxide, acne, OTC switch
FibroBiologics, CYPS317, psoriasis, human dermal fibroblast spheroids, Society for Investigative Dermatology